The combination of anti-PD-1/PD-L1 immunotherapy with other anti-tumor agents that overcome these specific properties will significantly improve the therapeutic effect of anti-PD-1/PD-L1 immunotherapy in PC. This evidence concerns the gene PDCD1 and neoplasm.